Real-world Cardiovascular Outcomes Associated With Degarelix vs Leuprolide for Prostate Cancer Treatment

Overview of attention for article published in JAMA Network Open, October 2021

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (93rd percentile)
Average Attention Score compared to outputs of the same age and source

Mentioned by

news: 3 news outlets
policy: 1 policy source

twitter: 15 X users
facebook: 1 Facebook page

Readers on

mendeley: 48 Mendeley

So far, Altmetric has seen 17 X posts from 15 X users, with an upper bound of 82,526 followers.

RT @BertrandTOMBAL: @DrAndrewLoblaw @SbrtSean In the US, close to 70% of patients switch from degarelix to leuprolide, thus blurring RWE ht…

@DrAndrewLoblaw @SbrtSean In the US, close to 70% of patients switch from degarelix to leuprolide, thus blurring RWE https://t.co/O633F6TYmk

@drjohnm @KBibbinsDomingo https://t.co/WRpwj4epCf Emulation of the PRONOUNCE trial, while the PRONOUNCE trial was still ongoing

RT @JoshuaDWallach: Really excited about our new paper in @JAMANetworkOpen. We set out to emulate (predict the population & results) of an…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 13 additional X posts.